Visual Loss in Biostimulator Injectables: A Review of Incidence, Risk Factors, Etiology and Management Proposal
- 20 November 2025
- journal article
- review article
- Published by Springer Nature in Aesthetic Plastic Surgery
- Vol. 50 (5) , 1994-2005
Abstract
Background As the popularity of non-hyaluronic acid (HA) injectables such as biostimulators rise in medical aesthetics, so have the rates of complications related to these injectables, including that of iatrogenic visual loss from vascular occlusion. Methods The authors conducted a systematic review of the available literature on visual loss related to the most widely used biostimulator injectables including calcium hydroxylapatite (CaHA), polycaprolactone (PCL), poly-L-lactic acid (PLLA), and poly-D,L-lactic acid (PDLLA) to provide a report on the incidence of such events, as well as evidence-based management protocols. Results CaHA has at least 11 published cases of vascular occlusion causing visual impairment, most involving the nasal dorsum. PLLA has two confirmed reports of visual loss, one from injection to periorbital/nasal region, and another from injection to the temple. PDLLA- carboxy-methylcellulose (CMC) has two reported cases of visual loss, one from injection to the forehead, another from injection to glabella region. PDLLA-HA has one reported case of visual loss from posterior ischemic optic neuropathy (PION). PCL has no published cases of blindness but one case of facial artery embolism. An evidence-based management protocol includes a sound knowledge of anatomy and injectable characteristics, timely recognition of symptoms, immediate actions such as starting intraocular lowering agents and sending to the ophthalmologist, as well as supportive therapy such as hyperbaric oxygen, anti-inflammatory and anti-coagulation therapy. Conclusions Our review and proposed management protocol is timely in guiding physicians of the recognition and management of vascular occlusion causing visual loss by biostimulator injectables, especially in a time of rising popularity of these injectables in medical aesthetics. Level of Evidence V This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266.Keywords
This publication has 57 references indexed in Scilit:
- Multifocal strokes and vision loss from PDLLA filler injectionsJournal of Stroke and Cerebrovascular Diseases, 2024
- Standardized approach to treatment of retinal artery occlusion after intraarterial injection of soft tissue fillers: EYE-CODEJournal of the American Academy of Dermatology, 2022
- Reversal of Post-filler Vision Loss and Skin Ischaemia with High-Dose Pulsed Hyaluronidase InjectionsAesthetic Plastic Surgery, 2019
- A Cadaveric Feasibility Study of the Intraorbital Cannula Injections of Hyaluronidase for Initial Salvation of the Ophthalmic Artery OcclusionAesthetic Plastic Surgery, 2015
- Blindness after calcium hydroxylapatite injection at noseJournal of Plastic, Reconstructive & Aesthetic Surgery, 2014
- Iatrogenic Occlusion of the Ophthalmic Artery After Cosmetic Facial Filler InjectionsJAMA Ophthalmology, 2014
- Iatrogenic Retinal Artery Occlusion Caused by Cosmetic Facial Filler InjectionsAmerican Journal of Ophthalmology, 2012
- Early Hyperbaric Oxygen Treatment for Nonarteritic Central Retinal Artery ObstructionAmerican Journal of Ophthalmology, 2012
- The Use of Hyperbaric Oxygen Therapy in OphthalmologySurvey of Ophthalmology, 2008
- Central Retinal Artery Occlusion: Visual OutcomeAmerican Journal of Ophthalmology, 2005